moatshark My

All holdings

Bio-Rad Laboratories

BIO

Source: the SEC Form 13F filings of the managers we follow, latest for Q3 2026. How we use them

Managers holding
2
In their latest 13F (Q3 2026)
See who
Value held
$883m
Combined value at quarter end
Last quarter
1 bought
2 sold or trimmed
Fund portfolios
2
Funds holding it
See which
Price at Q2 ’26 end
$293.61
+5.3% in the quarter

Prices here are quarter-end prices implied by the 13F filings. Today’s price on Yahoo Finance

Share price change by quarter

+22.5%Q3 ’24
-1.8%Q4 ’24
-25.9%Q1 ’25
-0.9%Q2 ’25
+16.2%Q3 ’25
+8.1%Q4 ’25
-8.0%Q1 ’26
+5.3%Q2 ’26
Q3 ’24: +22.5%; Q4 ’24: -1.8%; Q1 ’25: -25.9%; Q2 ’25: -0.9%; Q3 ’25: +16.2%; Q4 ’25: +8.1%; Q1 ’26: -8.0%; Q2 ’26: +5.3%

Change in the quarter-end price implied by managers’ 13F filings, adjusted for stock splits. Excludes dividends.

Managers holding it, by quarter

3Q4 ’23
3Q1 ’24
3Q2 ’24
3Q3 ’24
3Q4 ’24
3Q1 ’25
3Q2 ’25
3Q3 ’25
3Q4 ’25
3Q1 ’26
2Q2 ’26
0Q3 ’26
Q4 ’23: 3; Q1 ’24: 3; Q2 ’24: 3; Q3 ’24: 3; Q4 ’24: 3; Q1 ’25: 3; Q2 ’25: 3; Q3 ’25: 3; Q4 ’25: 3; Q1 ’26: 3; Q2 ’26: 2; Q3 ’26: 0

Counts the managers on this site whose 13F for that quarter includes Bio-Rad Laboratories.

Who holds it

Each manager’s latest 13F, sorted by how much of their portfolio it is. Changes are against their previous quarter.

Managers holding Bio-Rad Laboratories
First Pacific Advisors (FPA)1.5%$118m$118mTrimmed -1.3%11 qtrs
First Eagle Investment Management1.3%$765m$765mAdded +0.1%13 qtrs

Download the holders: CSV · JSON · Markdown

About the company

Sector
Technology · Laboratory Analytical Instruments
Incorporated in
Delaware
Financial year ends
31 December
SEC filings
Annual reports and other filings on EDGAR

Revenue and profit

$2.1bn2013
$2.0bn2015
$2.2bn2017
$2.3bn2019
$2.9bn2021
$2.7bn2023
$2.6bn2025
2013: $2.1bn; 2014: $2.2bn; 2015: $2.0bn; 2016: $2.1bn; 2017: $2.2bn; 2018: $2.3bn; 2019: $2.3bn; 2020: $2.5bn; 2021: $2.9bn; 2022: $2.8bn; 2023: $2.7bn; 2024: $2.6bn; 2025: $2.6bn
Bio-Rad Laboratories revenue and net income by year
YearRevenueNet income
2025$2.6bn$760m
2024$2.6bn−$1.8bn
2023$2.7bn−$637m
2022$2.8bn−$3.6bn
2021$2.9bn$4.3bn
2020$2.5bn$3.8bn
2019$2.3bn$1.8bn
2018$2.3bn$366m
2017$2.2bn$122m
2016$2.1bn$26.0m
2015$2.0bn$109m
2014$2.2bn$88.8m
2013$2.1bn$77.8m

From the company’s XBRL financial statements filed with the SEC, for each financial year. Gaps mean the company didn’t report that figure in a standard form.

Sold out last quarter

In fund portfolios

US-registered funds run by these managers that hold Bio-Rad Laboratories, from their latest N-PORT filings.

Funds holding Bio-Rad Laboratories
First Eagle Global FundFirst Eagle Investment Management0.8%$611m31 Jul 2026
FPA Crescent FundFirst Pacific Advisors (FPA)0.6%$71.8m30 Jun 2026